These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 22190972)

  • 1. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
    Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
    Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
    Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
    Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.
    Adhikaree J; Moreno-Vicente J; Kaur AP; Jackson AM; Patel PM
    Cells; 2020 Jan; 9(2):. PubMed ID: 31973059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy.
    Feng P; Li Z; Li Y; Zhang Y; Miao X
    Front Immunol; 2022; 13():799509. PubMed ID: 35799789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.
    Datsi A; Sorg RV
    Front Immunol; 2021; 12():770390. PubMed ID: 34795675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The network of immunosuppressive pathways in glioblastoma.
    Mangani D; Weller M; Roth P
    Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
    Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
    Elife; 2020 Feb; 9():. PubMed ID: 32014107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.